Jafri Adeel, Hubbard Rachel, Hussain Syed A
Department of Oncology and Metabolism, Sheffield Teaching Hospital, Sheffield, South Yorkshire S10 2JF, United Kingdom.
Department of Radiology, Sheffield Teaching Hospital, Sheffield, South Yorkshire S10 2JF, United Kingdom.
Bladder (San Franc). 2025 May 20;12(2):e21200045. doi: 10.14440/bladder.2024.0075. eCollection 2025.
The combination of immune checkpoint inhibitors and radiotherapy (RT) is emerging as a promising therapeutic approach for advanced bladder cancer. However, clinical evidence of the abscopal effect in this context is still limited.
Presented here is a 61-year-old female with high-grade urothelial carcinoma who had initially undergone chemotherapy, followed by treatment with atezolizumab (an anti-programmed death-ligand 1 antibody). Due to disease progression and symptoms, she received palliative RT alongside continued immunotherapy. Post-RT staging scans showed a significant reduction in the size of the bladder mass and a marked improvement in the patient's quality of life. Although this case did not demonstrate a definite abscopal effect, it underscores the potential benefits of combining immunotherapy and RT.
The observed outcomes suggest that this combination can effectively manage advanced bladder cancer, highlighting the need for further research to refine and optimize these treatment strategies.
免疫检查点抑制剂与放射治疗（RT）联合应用正成为晚期膀胱癌一种有前景的治疗方法。然而，在这种情况下远隔效应的临床证据仍然有限。
本文介绍了一名61岁的高级别尿路上皮癌女性患者，她最初接受了化疗，随后接受了阿替利珠单抗（一种抗程序性死亡配体1抗体）治疗。由于疾病进展和症状，她在继续免疫治疗的同时接受了姑息性放疗。放疗后分期扫描显示膀胱肿块大小显著减小，患者生活质量明显改善。虽然该病例未显示明确的远隔效应，但它强调了免疫治疗与放疗联合应用的潜在益处。
观察到的结果表明，这种联合治疗可以有效管理晚期膀胱癌，凸显了进一步研究以完善和优化这些治疗策略的必要性。
